{"id":52005,"date":"2022-12-14T23:02:14","date_gmt":"2022-12-14T22:02:14","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/applied-dna-announces-fourth-quarter-and-fiscal-year-2022-financial-results\/"},"modified":"2022-12-14T23:02:14","modified_gmt":"2022-12-14T22:02:14","slug":"applied-dna-announces-fourth-quarter-and-fiscal-year-2022-financial-results","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/applied-dna-announces-fourth-quarter-and-fiscal-year-2022-financial-results\/","title":{"rendered":"Applied DNA Announces Fourth Quarter and Fiscal Year 2022 Financial Results"},"content":{"rendered":"
\n

\n– Delivers 17% Revenue Growth Q\/Q and 101% Y\/Y –<\/i>\n<\/p>\n

\n– Cash and Cash Equivalents at $15.2 Million –<\/i>\n<\/p>\n

\n– Company to Hold Conference Call and Webcast Today, Wednesday, December 14, 2022, at 4:30 PM ET –<\/i>\n<\/p>\n

STONY BROOK, N.Y.–(BUSINESS WIRE)–$APDN<\/a> #LinearDNA<\/a>—Applied DNA Sciences, Inc.<\/a> (NASDAQ: APDN) (\u201cApplied DNA\u201d or the \u201cCompany\u201d), a leader in PCR-based DNA technologies, today announced consolidated financial results for the fourth quarter and fiscal year ended September 30, 2022.\n<\/p>\n

<\/a><\/p>\n

\n\u201cApplied DNA delivered four consecutive quarters of year-over-year revenue increases and a second consecutive record revenue year in fiscal 2022 while simultaneously executing on our long-term strategy and vision to build a diversified PCR-based DNA technologies company in biotechnology, clinical diagnostics, and supply chain traceability,\u201d stated Dr. James A. Hayward, president and CEO. \u201cOver the past 12 months, our LineaRx subsidiary generated volumes of preclinical data to strengthen the case for the biotherapeutic industry\u2019s adoption of enzymatically-produced linear DNA (linearDNA\u2122) for the manufacture of genetic medicines, expanded the menu of molecular diagnostic tests at our Applied DNA Clinical Labs (\u201cADCL\u201d) subsidiary, and moved to capitalize on U.S. federal enforcement of the Uyghur Forced Labor Prevention Act (the \u201cUFLP Act\u201d) as a driver of broader CertainT\u00ae platform adoption by the textiles industry.\n<\/p>\n

\n\u201cStrategically, we committed to our biotherapeutics opportunity as the chief driver of long-term shareholder value while working to evolve our ADCL and supply chain traceability segments towards positive cash flow to support the value-creating potential of our LinearDNA platform,\u201d continued Dr. Hayward. \u201cOperationally, we undertook a detailed assessment to reduce costs associated with our largest COVID-19 testing contract, our chief driver of revenue. In fiscal 2023, we will continue to manage our costs associated with this contract, while at the same time, working to close sales opportunities for our to-be-launched pharmacogenetic testing services. In our supply chain traceability segment, we worked to educate key policy makers, customers, and enforcement agencies on CertainT, our textile traceability platform, ahead of the implementation of the UFLP Act. As enforcement of the UFLP Act is expected to become ubiquitous at U.S. ports, we believe that CertainT is well positioned to help customers meet its compliance requirements.\u201d\n<\/p>\n

\nConcluded Dr. Hayward, \u201cOur strategic priorities in fiscal 2023 are twofold: first, we are focused on capturing new sales opportunities and effecting gross margin improvements in our ADCL and supply chain traceability segments empowered by the commercialization of our pharmacogenomics (\u201cPGx\u201d) testing platform and the broader implementation of the UFLP Act, respectively; second, we are focused on making the necessary investments in our LinearDNA platform to support the growth of this business segment from a small-scale CRO to a larger-scale CDMO capable of capturing promising opportunities in genetic medicines, including the use of linearDNA IVT templates to produce mRNA therapeutics. Historically, the gating factor to broader linearDNA adoption has been our lack of cGMP production capacity which we are moving to remedy over the course of the fiscal year and expect to culminate in the establishment of an initial cGMP production capacity by the end of calendar year 2023.\u201d\n<\/p>\n

\nFourth Quarter 2022 Financial Highlights<\/b>\n<\/p>\n

\nTotal revenues increased 17% to $3.6 million, which included $2.9 million in clinical laboratory service revenues (COVID-19 testing revenue). This compares with total revenues of $3.0 million in the prior fiscal year period, which included $1.6 million of COVID-19 testing revenue.\n<\/p>\n

\nThe year-over-year increase was offset by a decrease in product revenues of $713 thousand due to a decrease in sales of DNA concentrate within a textile supply chain, as well a decline in sales of our molecular diagnostics (MDx) test kits and supplies and a decrease in service revenue of $70 thousand.\n<\/p>\n

\nGross profit was $417 thousand, or 12%, compared to $992 thousand, or 33%, in the prior fiscal year period. The decline in gross margin was primarily the result of a higher portion of clinical laboratory service revenues coming from managed services testing contracts that carry higher costs compared to ADCL’s surveillance testing contracts. To a lesser extent, the decline was due to product sales mix as product revenues in the prior fiscal year period included sales of diagnostic test kit and supplies and DNA concentrate for supply chains serving the textiles industry that are at a higher gross margin.\n<\/p>\n

\nTotal operating expenses were $4.8 million compared to $5.5 million in the prior fiscal year period, reflecting the absence of a $822 thousand impairment charge related to goodwill and the remaining net book value of intangible assets incurred in the prior fiscal year period and to a lesser extent, decreases in research and development expenses of $313 thousand. The decrease in operating expenses was offset by an increase of $420 thousand in selling, general and administrative expenses attributable to an increase in insurance expense of approximately $209 thousand and an increase in bad debt expense of approximately $237 thousand for the reserve of a customer balance that was deemed to be uncollectible.\n<\/p>\n

\nOperating loss was $4.4 million compared to an operating loss of $4.5 million in the prior fiscal year period.\n<\/p>\n

\nExcluding non-cash expenses, Adjusted EBITDA was negative $3.4 million compared to negative $3.3 million in the prior fiscal year period. See below for information regarding non-GAAP measures.\n<\/p>\n

\nCash and cash equivalents of $15.2 million at September 30, 2022, include proceeds from a public offering conducted in the quarter of common stock and two series of warrants for gross proceeds of $12.0 million, and the exercise of warrants in connection with this offering for additional net proceeds of $3.7 million.\n<\/p>\n

\nFiscal 2022 Financial Highlights<\/b>\n<\/p>\n

\nTotal revenues increased 101% to $18.2 million, which included $15.5 million in clinical laboratory service revenues (COVID-19 test revenue). This compares with total revenues of $9.0 million in the prior fiscal year period, which included $4.8 million of COVID-19 test revenue.\n<\/p>\n

\nThe year-over-year increase was offset by a decrease in product revenues of $1.4 million reflecting decreased sales of our MDx test kits and supplies to an ADCL COVID-19 customer and, to a lesser extent, a decrease in the sale of DNA concentrate for textiles supply chains recorded in the prior fiscal year period and a decrease in service revenues of $179 thousand reflecting research and developments projects completed in the prior fiscal year period.\n<\/p>\n

\nTotal operating expenses increased 7% to $19.0 million from $17.8 million in the prior fiscal year period. The increase is attributable to an increase in selling, general and administrative expenses of $2.3 million, offsetting a decrease in research and development expenses of $238 thousand and the absence of a $822 thousand impairment charge related to goodwill and the remaining net book value of intangible assets incurred in the prior fiscal year period.\n<\/p>\n

\nOperating loss was $14.0 million compared to $13.3 million in the prior fiscal year period.\n<\/p>\n

\nExcluding non-cash expenses, Adjusted EBITDA was negative $9.9 million compared to negative $10.1 million in the prior fiscal year period. See below for information regarding non-GAAP measures.\n<\/p>\n

\nWarrants balance at September 30, 2022 stood at 7.3 million. Approximately 2.2 million of these warrants have exercise prices ranging from $2.80 to $2.84 per warrant share, which, if exercised, could result in exercise proceeds to the Company of approximately $6.3 million; 5.1 million of these warrants have an exercise price of $4.00 per warrant share, which, if exercised, could result in total exercise proceeds of approximately $20.3 million. Of the 5.1 million warrants, 2.1 million expire in September 2023, which, if exercised, would total proceeds of $8.4 million.\n<\/p>\n

\nFourth Quarter and Full Year Fiscal 2022 Conference Call Information<\/b>\n<\/p>\n

\nThe Company will hold a conference call and webcast to discuss its fourth quarter and fiscal year 2022 financial results on Wednesday, December 14, 2022, at 4:30 PM ET. To participate on the conference call, please follow the instructions below. While every attempt will be made to answer investors\u2019 questions on the Q&A portion of the call, not all questions may be answered.\n<\/p>\n

\nTo Participate:<\/b>\n<\/p>\n